Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Vets warned of monensin toxicity in dogs
dog walking
So far, almost all reports involve farm dogs but due to the bolus regurgitation process, dogs walked on farmland are also at risk.
SPC for Kexxtone changed after rise in accidental exposure reports
 
Veterinary surgeons are being warned of the risks of monensin exposure to non-target species.

In 2015, the Veterinary Medicines Directorate (VMD) saw an increase in reports of accidental canine exposure to Kexxtone 32.4g (monensin), the drug used in cattle feed to control ketosis.

Reported symptoms included neurological issues, such as seizures, lethargy, muscular problems, locked jaws, problems with balance, confusion, vomiting and death.

So far, almost all reports involve farm dogs but due to the bolus regurgitation process, dogs walked on farmland are also at risk.

As a result, the VMD requested that the following warning be added to the Summary of Product Characteristics (SPC):

'Do not allow dogs, horses, other equines or guinea fowl access to formulations containing monensin. Due to the risk of bolus regurgitation, do not allow these species access to areas where treated cattle have been kept. Ingestion or oral exposure to monensin can be fatal in these species.'

Writing in Veterinary Record letters, the VMD suggested that when prescribing Kexxtone, vets should advise clients of the dangers to non-target species, whilst also remaining aware of the effects of monensin when dealing with cases that present neurological or myopathic problems.

Vets are encouraged to report all adverse reactions to the applicable marketing authorisation holder, or to the VMD via: www.gov.uk/report-veterinary-medicine-problem

Become a member or log in to add this story to your CPD history

FIVP launches CMA remedies survey

News Story 1
 FIVP has shared a survey, inviting those working in independent practice to share their views on the CMA's proposed remedies.

The Impact Assessment will help inform the group's response to the CMA, as it prepares to submit further evidence to the Inquiry Group. FIVP will also be attending a hearing in November.

Data will be anonymised and used solely for FIVP's response to the CMA. The survey will close on Friday, 31 October 2025. 

Click here for more...
News Shorts
CMA to host webinar exploring provisional decisions

The Competition and Markets Authority (CMA) is to host a webinar for veterinary professionals to explain the details of its provisional decisions, released on 15 October 2025.

The webinar will take place on Wednesday, 29 October 2025 from 1.00pm to 2.00pm.

Officials will discuss the changes which those in practice may need to make if the provisional remedies go ahead. They will also share what happens next with the investigation.

The CMA will be answering questions from the main parties of the investigation, as well as other questions submitted ahead of the webinar.

Attendees can register here before Wednesday, 29 October at 11am. Questions must be submitted before 10am on 27 October.

A recording of the webinar will be accessible after the event.